CENTRE HOSPITALIER UNIVERSITAIRE PONTCHAILLOU;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -;UNIVERSITE LIBRE DE BRUXELLES;UNIVERSITE DE RENNES 1
The present invention relates to methods and reagents for the treatment of melanoma and/or of metastatic melanoma that directly or indirectly target TYRP1 RNA transcript. The invention also relates to methods for predicting if a melanoma patient will be therapeutically responsive to such methods of treatment and reagents, and to methods for assessing the effectiveness of such methods of treatment and reagents. The invention further relates to a combination of biological markers that allows the prediction of melanoma patients' survival irrespective of the treatment administered.
